Tag Archives: STML

Analysts Are Bullish on These Healthcare Stocks: Stemline Therapeutics Inc (STML), Alimera (ALIM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Stemline Therapeutics Inc (STML – Research Report), Alimera (ALIM – Research Report) and Immunomedics (IMMU – Research Report) with bullish sentiments. Stemline

Cowen & Co. Maintains Their Buy Rating on Stemline Therapeutics Inc (STML)

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Stemline Therapeutics Inc (STML – Research Report). The company’s shares closed last Monday at $10.52. According to TipRanks.com, Peaker is a 1-star analyst with

Cowen & Co. Keeps a Buy Rating on Stemline Therapeutics Inc (STML)

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Stemline Therapeutics Inc (STML – Research Report). The company’s shares closed last Monday at $10.83. According to TipRanks.com, Peaker is a 3-star analyst with

Cowen & Co. Reaffirms Their Buy Rating on Stemline Therapeutics Inc (STML)

Cowen & Co. analyst Boris Peaker maintained a Buy rating on Stemline Therapeutics Inc (STML – Research Report) today. The company’s shares closed on Friday at $14.86. According to TipRanks.com, Peaker is a 3-star analyst with an average return of

Stemline Therapeutics Inc (STML) Gets a Buy Rating from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Stemline Therapeutics Inc (STML – Research Report), with a price target of $35. The company’s shares closed yesterday at $10.22. Selvaraju commented: “Our 12-month price

Stemline Therapeutics Inc (STML) Received its Third Buy in a Row

After J.P. Morgan and Roth Capital gave Stemline Therapeutics Inc (NASDAQ: STML) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Ram Selvaraju reiterated a Buy rating on Stemline Therapeutics Inc today and